Literature DB >> 19439487

Oseltamivir (tamiflu) is a substrate of peptide transporter 1.

Takuo Ogihara1, Takashi Kano, Tamae Wagatsuma, Sho Wada, Hikaru Yabuuchi, Shigeki Enomoto, Kaori Morimoto, Yoshiyuki Shirasaka, Shoko Kobayashi, Ikumi Tamai.   

Abstract

Oseltamivir, an ester-type prodrug of the neuraminidase inhibitor [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), has been developed for the treatment of A and B strains of the influenza virus but has neuropsychiatric and other side effects. In this study, we characterized the transport across intestinal epithelial cells and the absorption of oseltamivir in rats. Uptake by Caco-2 cells (human carcinoma cell line) and HeLa cells transfected with peptide transporter 1 (HeLa/PEPT1) was time- and temperature-dependent and was inhibited by typical PEPT1 inhibitors such as glycyl-sarcosine (Gly-Sar). The uptake by Caco-2 cells and HeLa/PEPT1 was saturable, with similar K(m) values. Oseltamivir absorption in adult rats was greatly reduced by simultaneous administration of milk, casein, or Gly-Sar. Furthermore, the plasma and brain concentrations of oseltamivir were higher in fasting than in nonfasting rats after oral administration. These results suggest that oseltamivir is a substrate of PEPT1 and that PEPT1 is involved in its intestinal absorption.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19439487     DOI: 10.1124/dmd.109.026922

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Intestinal adaptation for oligopeptide absorption via PepT1 after massive (70%) mid-small bowel resection.

Authors:  Srivats Madhavan; Jeffrey S Scow; Rizwan M Chaudhry; Munenori Nagao; Ye Zheng; Judith A Duenes; Michael G Sarr
Journal:  J Gastrointest Surg       Date:  2010-12-18       Impact factor: 3.452

Review 3.  Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.

Authors:  Susan M Abdel-Rahman; Jason G Newland; Gregory L Kearns
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

4.  Species-dependent uptake of glycylsarcosine but not oseltamivir in Pichia pastoris expressing the rat, mouse, and human intestinal peptide transporter PEPT1.

Authors:  Yongjun Hu; Xiaomei Chen; David E Smith
Journal:  Drug Metab Dispos       Date:  2012-04-09       Impact factor: 3.922

5.  The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.

Authors:  Yuki Suzaki; Naoto Uemura; Makoto Takada; Tetsuji Ohyama; Akiko Itohda; Takuya Morimoto; Hiromitsu Imai; Hajime Hamasaki; Akihiro Inano; Masakiyo Hosokawa; Masato Tateishi; Kyoichi Ohashi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-07       Impact factor: 2.953

6.  Differentiating passive from transporter-mediated uptake by PepT1: a comparison and evaluation of four methods.

Authors:  Jeffrey S Scow; Srivats Madhavan; Rizwan M Chaudhry; Ye Zheng; Judith A Duenes; Michael G Sarr
Journal:  J Surg Res       Date:  2011-03-12       Impact factor: 2.192

Review 7.  Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.

Authors:  Amanda K Sullins; Susan M Abdel-Rahman
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

8.  Role of the intestinal peptide transporter PEPT1 in oseltamivir absorption: in vitro and in vivo studies.

Authors:  Agnès Poirier; Sara Belli; Christoph Funk; Michael B Otteneder; Renée Portmann; Katja Heinig; Eric Prinssen; Stanley E Lazic; Craig R Rayner; Gerhard Hoffmann; Thomas Singer; David E Smith; Franz Schuler
Journal:  Drug Metab Dispos       Date:  2012-05-14       Impact factor: 3.922

9.  Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.

Authors:  Nao Kawaguchi; Hiroki Koshimichi; Toru Ishibashi; Toshihiro Wajima
Journal:  Clin Drug Investig       Date:  2018-11       Impact factor: 2.859

10.  Diabetes downregulates peptide transporter 1 in the rat jejunum: possible involvement of cholate-induced FXR activation.

Authors:  Li-Min Liang; Jun-Jie Zhou; Feng Xu; Pei-Hua Liu; Lan Qin; Li Liu; Xiao-Dong Liu
Journal:  Acta Pharmacol Sin       Date:  2020-04-27       Impact factor: 7.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.